From bench to retina clinic

The lab is led by a practicing vitreoretinal surgeon, and that clinical vantage point is wired into how we choose problems. Patients with severe retinal degeneration ask, in clinic, about treatments they have read about — gene therapies, photoswitches, retinal prostheses. The honest answers depend on details (visual acuity expectations, durability, side-effect profile, eligibility) that the preclinical literature often does not address head-on.

This thread of the lab does two things:

• Lets clinical bottlenecks shape the bench. Visual outcome measures that matter to patients, durability of restored function, dose-response in the human eye, the realistic geometry of intravitreal delivery — these become target metrics for our mechanistic and optimization work, rather than afterthoughts.
• Translates bench findings into trial-relevant questions. Mechanistic results from the lab inform candidate biomarkers, outcome measures, and trial design considerations for the photoswitch programs and for related therapies.

Topics from earlier work that connect here include retinal signaling, metabolomic and proteomic markers of inherited retinal disease, and global disparities in vision loss — all of which surface again as one moves from preclinical to clinical contexts.

Replace this placeholder note with specific projects, collaborations, and clinical resources as they develop.